Effect of dapagliflozin on COVID-19 infection and risk of hospitalization
ConclusionsUse of dapagliflozin prior to SARS-CoV-2 infection was not associated with an increased risk of hospitalization, ICU admission, mortality or progression to severe COVID-19. However, it was associated with an increased risk of susceptibility to COVID-19 infection.
Source: Journal of Antimicrobial Chemotherapy - Category: Microbiology Source Type: research
More News: Chemotherapy | Coronavirus | COVID-19 | Dapagliflozin | Forxiga | Microbiology | SARS | Statistics | Study